Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder

Leukemia Research

Volumn 32, Issue 1, 2008, Pages 169-171

  Ng, Heng Joo ^a   Tan, Daryl C L ^a   Yiu, Richard C ^a   How, Gee Fung ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Hypereosinophilia; Imatinib; Molecular response

Indexed keywords

IMATINIB;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COUGHING; DIAGNOSTIC IMAGING; EOSINOPHIL COUNT; FACE EDEMA; FEVER; FIP1L1 GENE; FOLLOW UP; FUSION GENE; GENE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HYPEREOSINOPHILIC SYNDROME; IMAGE ANALYSIS; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PDGFRA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; RESTRICTIVE CARDIOMYOPATHY; SYMPTOM;

ADULT; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MUTATION; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REMISSION INDUCTION;

EID: 36148951734     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.04.004     Document Type: Article

References (6)

1. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 13 (2003) 1201-1214
2. Pardanani A., Ketterling R.P., Li C.Y., Patnaik M.M., Wolanskyj A.P., Elliott M.A., et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 30 8 (2006) 965-970
3. Bain B., Pierre R., Imbert M., Vardiman J.W., Brunning R.D., and Flandrin G. Chronic eosinophilic leukemia and hypereosinophilic syndrome. In: Jaffe E.S.&l.;E.A. (Ed). World Health Organization classification of tumours: tumours of haematopoietic and lymphoid tissues (2001), Lyon:IARC Press 29-31
4. Helbig G., Stella-Holowiecka B., Grosicki S., Bober G., Krawczyk M., Wojnar J., et al. The results of imatinib therapy for patients with primary eosinophilic disorders. Eur J Haematol 76 6 (2006) 535-536
5. Rotoli B., Catalano L., Galderisi M., Luciano L., Pollio G., Guerriero A., et al. Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. Leuk Lymphoma 45 12 (2004) 2503-2507
6. Ascione L., De Michele M., Accadia M., Spadaro P., Rumolo S., and Tuccillo B. Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor. Eur J Echocardiogr 5 5 (2004) 386-390